Certa H, Fedtke N, Wiegand H J, Müller A M, Bolt H M
Hüls Aktiengesellschaft, DUV-Ps/Biologie-Toxikologie, Marl, Germany.
Arch Toxicol. 1996;71(1-2):112-22. doi: 10.1007/s002040050365.
Only weak oestrogenic activity has been reported for p-alkylphenols compared with the physiological hormone 17 beta-estradiol. Despite the low potency, there is concern that due to bioaccumulation oestrogenically efficient blood levels could be reached in humans exposed to trace levels of p-alkylphenols. To address these concerns, toxicokinetic studies with p-tert-octylphenol [OP; p-(1,1,3,3-tetramethylbutyl)-phenol] as a model compound have been conducted in male Wistar rats. OP blood concentrations were determined by GC-MS in rats receiving either single oral (gavage) applications of 50 or 200 mg OP/kg body wt or a single intravenous injection of 5 mg/kg body wt. The OP blood concentration was approximately 1970 ng/ml immediately after a single intravenous application, decreased rapidly within 30 min, and was no longer detectable 6-8 h after application. The curve of blood concentration vs time was used to calculate an elimination half-life of 310 min. OP was detected in blood as early as 10 min after gavage administration, indicating rapid initial uptake from the gastrointestinal tract; maximal blood levels reached 40 and 130 ng/ml after applications of 50 and 200 mg/kg, respectively. Using the area under the curve (AUC) of blood concentration vs time, low oral bioavailabilities of 2 and 10% were calculated for the 50 and 200 mg/kg groups, respectively. OP toxicokinetics after repeated administration was investigated in male Wistar rats receiving daily gavage administrations of 50 or 200 mg OP/kg body wt for 14 consecutive days. Profiles of OP blood concentration vs time determined on day 1 and day 14 were similar, indicating that repeated oral gavage administration did not lead to increased blood concentrations. Another group of rats received OP via drinking water saturated with OP (approximately 8 mg/l, corresponding to a mean daily dose of approximately 800 micrograms/kg) over a period of up to 28 days. OP was not detected in any blood sample from animals treated via drinking water (detection limit was 1-5 ng/ml blood). OP concentrations were also analysed in tissues obtained from the repeated gavage (14 days) and drinking water groups (14 and 28 days). In the 50 mg/kg group, low OP concentrations were detected in fat and liver from some animals at average concentrations of 10 and 7 ng/g tissue, respectively. OP was not detected in the other tissues analysed from this group. In the 200 mg/kg group, OP was found in all tissues analysed except testes (fat, liver, kidney, muscle, brain and lung had average concentrations of 1285, 87, 71, 43, 9 and 7 ng/g tissue, respectively). OP was not detected in tissues of animals receiving OP via drinking water for 14 or 28 days, except in muscle and kidney tissue of one single animal receiving OP for 14 days. Using rat liver fractions it was demonstrated that OP was conjugated via glucuronidation and sulphation in vitro. A Vmax of 11.24 nmol/(min * mg microsomal protein) and a Km of 8.77 mumol/l were calculated for enzyme-catalysed OP glucuronidation. For enzyme-catalysed sulphation, a Vmax of 2.85 nmol/(min * mg protein) and a Km of 11.35 mumol/l were calculated. The results indicate that OP does not bioaccumulate in rats receiving low oral doses, in agreement with the hypothesis of a rapid first-pass elimination of OP by the liver after oral ingestion, via glucuronidation and sulphation. Only if these detoxification pathways are saturated may excessive doses lead to bioaccumulation.
与生理激素17β - 雌二醇相比,对烷基酚仅表现出微弱的雌激素活性。尽管效力较低,但人们担心,由于生物累积作用,接触痕量对烷基酚的人类可能会达到具有雌激素活性的有效血液水平。为了解决这些担忧,以对叔辛基酚[OP;对 - (1,1,3,3 - 四甲基丁基) - 苯酚]作为模型化合物,在雄性Wistar大鼠中进行了毒代动力学研究。通过气相色谱 - 质谱法测定接受单次口服(灌胃)50或200 mg OP/kg体重剂量或单次静脉注射5 mg/kg体重剂量的大鼠体内的OP血液浓度。单次静脉给药后,OP血液浓度在给药后立即约为1970 ng/ml,在30分钟内迅速下降,给药后6 - 8小时不再可检测到。血液浓度与时间的曲线用于计算消除半衰期为310分钟。灌胃给药后10分钟血液中就检测到了OP,表明其从胃肠道快速初始吸收;分别给予50和200 mg/kg剂量后,最大血液浓度达到40和130 ng/ml。利用血液浓度与时间曲线下面积(AUC),计算出50和200 mg/kg组的口服生物利用度分别为2%和10%。在连续14天每天接受50或200 mg OP/kg体重灌胃给药的雄性Wistar大鼠中研究了重复给药后的OP毒代动力学。第1天和第14天测定的OP血液浓度与时间曲线相似,表明重复口服灌胃给药不会导致血液浓度升高。另一组大鼠在长达28天的时间内通过饮用含OP的饱和水(约8 mg/l,相当于平均每日剂量约800微克/kg)摄入OP。在通过饮用水处理的动物的任何血液样本中均未检测到OP(检测限为1 - 5 ng/ml血液)。还分析了从重复灌胃(14天)和饮用水组(14天和28天)获得的组织中的OP浓度。在50 mg/kg组中,在一些动物的脂肪和肝脏中检测到低浓度的OP,平均浓度分别为10和7 ng/g组织。在该组分析的其他组织中未检测到OP。在200 mg/kg组中,除睾丸外,在所有分析的组织中均发现了OP(脂肪、肝脏、肾脏、肌肉、大脑和肺的平均浓度分别为1285、87、71、43、9和7 ng/g组织)。在通过饮用水接受OP处理14天或28天的动物组织中,除了一只接受OP处理14天的动物的肌肉和肾脏组织外,未检测到OP。利用大鼠肝脏组分证明,OP在体外通过葡萄糖醛酸化和硫酸化进行结合。计算出酶催化OP葡萄糖醛酸化的Vmax为11.24 nmol/(min * mg微粒体蛋白),Km为8.77 μmol/l。对于酶催化的硫酸化,计算出Vmax为2.85 nmol/(min * mg蛋白) 和Km为11.35 μmol/l。结果表明,在接受低口服剂量的大鼠中OP不会生物累积,这与口服摄入后肝脏通过葡萄糖醛酸化和硫酸化对OP进行快速首过消除的假设一致。只有当这些解毒途径饱和时,过量剂量才可能导致生物累积。